Skip to content
← Holders

Elmind Capital, LP

What Elmind Capital, LP reported holding on Form 13F for the quarter ended Sep 30, 2026.

CIK 2052213 · Filed Nov 16, 2026

Positions
30
Reported value
$403.8M
Opened
0
Closed
5
Other managers included
0

Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR

Quarters on file

  1. Dec 31, 2025$338.9M
    34 positions
  2. Mar 31, 2026$352.2M
    34 positions
  3. Jun 30, 2026$398M
    35 positions
  4. Sep 30, 2026$403.8M
    30 positions
SecuritySharesChangeValueOf portfolio
CLDXCelldex Therapeutics, Inc.
1.1M+12.1%$36M8.9%
LEGNLegend Biotech Corp
1.6M+175.1%$31.2M7.7%
SNDXSyndax Pharmaceuticals Inc
1.6M−13.5%$30.2M7.5%
COGTCogent Biosciences, Inc.
866.7K−26.0%$27.8M6.9%
RLAYRelay Therapeutics, Inc.
1.5M±0%$26.4M6.5%
AMLXAmylyx Pharmaceuticals, Inc.
894.8K+698.9%$26M6.4%
VRDNViridian Therapeutics, Inc.
1.2M+24.4%$25.2M6.2%
PCVXVaxcyte, Inc.
372.3K−17.7%$21.2M5.2%
URGNUroGen Pharma Ltd.
491.1K+309.3%$20M4.9%
TVTXTravere Therapeutics, Inc.
322.6K+10.3%$19M4.7%
CGEMCullinan Therapeutics, Inc.
962.8K+39.5%$14.8M3.7%
PHVSPharvaris N.V.
455.8K−13.3%$14.5M3.6%
VERAVera Therapeutics, Inc.
436.5K±0%$14.1M3.5%
CTMXCytomX Therapeutics, Inc.
4.6M±0%$12.4M3.1%
BEAMBeam Therapeutics Inc.
476.3K±0%$11.6M2.9%
NRIXNurix Therapeutics, Inc.
460K±0%$10.9M2.7%
SMMTSummit Therapeutics Inc.
493.8K±0%$8.4M2.1%
UTHRUnited Therapeutics Corp
15K±0%$8.1M2%
IMCRImmunocore Holdings plc
256.1K+215.7%$7.8M1.9%
KRYSKrystal Biotech, Inc.
22K±0%$7.3M1.8%
ALMSAlumis Inc.
749.6K+476.6%$5.5M1.4%
BCRXBiocryst Pharmaceuticals Inc
520K±0%$4.3M1.1%
STROSutro Biopharma, Inc.
228.3K+612.5%$3.7M0.9%
MBXMBX Biosciences, Inc.
61K−33.0%$3.6M0.9%
DBVTDBV Technologies S.A.
265K±0%$3.1M0.8%
SUPNSupernus, Inc.
70K±0%$3M0.7%
BMRNBioMarin Pharmaceutical Inc
47K±0%$2.8M0.7%
SEPNSepterna, Inc.
49.4K±0%$1.9M0.5%
ALECAlector, Inc.
915.9K+1.8%$1.7M0.4%
DSGNDesign Therapeutics, Inc.
107.9K±0%$1.4M0.3%